Clinical trials: Neurologic Dysfunction
Alzheimer Disease, Parkinson Disease
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
Primary Objective: The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device.
- Conditions
- Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration
- Trial name
- MemorEM (NCT07222605)
- Testing
- MemorEM
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- eQ8Health Corporation d/b/a CareONE Concierge
Neurogenic Urinary Bladder
Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction
The primary objective of the study was to evaluate the efficacy of Alfuzosin in comparison to Placebo on the detrusor Leak Point Pressure (LPP) in children and adolescents 2-16 years of age with elevated detrusor LPP of…
- Trial name
- ALFACHIN (NCT00549939)
- Testing
- Alfuzosin
- Where
- 18 sites in United States, Bulgaria and 16 more
- Volunteers
- 172 people
- Sponsor
- Sanofi
Dysmenorrhea, Dyspareunia
Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women
The purpose of the study is to evaluate the efficacy and safety of two doses of ERB-041 (75 mg and 150 mg) relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in…
- Conditions
- Dysmenorrhea, Dyspareunia, Endometriosis, Pelvic Pain
- Trial name
- NCT00318500
- Testing
- ERB-041
- Where
- 70 sites in United States, Australia and 5 more
- Volunteers
- 150 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Down Syndrome
A Study of ACI-24 in Adults With Down Syndrome
This study is a prospective multicenter, placebo-controlled, double-blind, randomized study to assess the effect of one dose ACI-24 versus placebo over a 74-week treatment period and 26-week safety follow-up period.
- Trial name
- NCT04373616
- Testing
- ACI-24
- Sponsor
- AC Immune SA
Dementia, Mild Cognitive Impairment
HOme-based Brain Monitoring With a GARment-EEG to Study Cognitive Decline in the Aging Population
This study will investigate the validity of the HOGAR EEG/PSG monitoring kit designed by Bitbrain as a tool for characterizing and assessing cognitive function in older adults, as well as for detecting and predicting cognitive…
- Conditions
- Dementia, Mild Cognitive Impairment, Dementia Alzheimers, Dementia, Mixed
- Trial name
- Hogar (NCT06993207)
- Testing
- Home Lab
- Where
- Spain
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Bitbrain
Disorientation, Cognitive Impairment
Evaluation of Safe Use of SECURIDRAP® SELFIA®
Interventional, multicenter, prospective and non-comparative clinical investigation carried out in 9 French establishments in order to assess the safety of the SÉCURIDRAP® SELFIA® bedding by mesasuring all the adverse events…
- Conditions
- Disorientation, Cognitive Impairment, Behavior Disorders
- Trial name
- SECURIDRAP (NCT05510401)
- Testing
- SECURIDRAP® SELFIA®
- Where
- 10 sites in France
- Volunteers
- 108 people
- Sponsor
- Groupe Mulliez-Flory
Mild Cognitive Impairment, Alzheimer's Disease
Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements
In a retrospective analysis of data from 1100 patients, disease-delaying effects of Cerefolin®/CerefolinNAC® were examined in terms of cognition.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease Related Disorders
- Trial name
- NCT01745198
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Pamlab, Inc.
Alzheimer Disease, Mild Cognitive Impairment
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol) such as longitudinal studies of aging…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
- Trial name
- NCT01518374
- Testing
- Florbetapir F 18
- Where
- 26 sites in United States
- Volunteers
- 1,768 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine in a 12-week treatment study if MEM 1003 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00257673
- Testing
- MEM 1003
- Where
- 57 sites in United States
- Volunteers
- 183 people
- Sponsor
- Memory Pharmaceuticals
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, as measured…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED (NCT04828122)
- Where
- 4 sites in United Kingdom
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
The proposed study is designed to evaluate the performance of the ALTOIDA™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Disorders, Cognitive Impairment
- Trial name
- AltoidaML (NCT02843529)
- Testing
- Altoida: neuropsychological, MRI, EEG and CSF biomarkers
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Altoida
Healthy Aging, Alzheimer's Disease
The Feasibility, Safety and Tolerability of VR-based Audiovisual Stimulation
This single-session, within-subject, sham-controlled early feasibility study evaluated the safety, tolerability, and feasibility of delivering 40 Hz audiovisual (gamma sensory) stimulation through a virtual reality (VR) headset…
- Conditions
- Healthy Aging, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- CFS (NCT06234930)
- Testing
- Audiovisual stimulation VR system
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Clarity Health Technologies, Inc
Ocular Motility Disorders, Strabismus
Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM)
This prospective, multicenter, multinational observational study evaluates the clinical validity of an AI-based quantitative eye movement analysis system (Glandy EOM) that analyzes smartphone-recorded 9-gaze videos.
- Conditions
- Ocular Motility Disorders, Strabismus, Extraocular Muscle Dysfunction, Thyroid Eye Disease
- Trial name
- GLANDY-EOM-VAL (NCT07623837)
- Testing
- Glandy EOM (AI-based quantitative eye movement analysis software)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- THYROSCOPE INC.
Dementia, Cognitive Impairment
Evaluation of Blood-Based Biomarkers and Remote Cognitive Assessment for Dementia Triage (SANDBOX)
Dementia is a leading cause of death in the UK, and long waits for diagnosis can delay access to care and treatment. The SANDBOX study is a research study in NHS Memory Clinics investigating whether providing clinicians with…
- Trial name
- SANDBOX (NCT07842029)
- Where
- 12 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Prima Mente
Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamic response of repeated intravenous infusions of BAN2401 in subjects with mild cognitive impairment (MCI) due to…
- Trial name
- NCT02094729
- Testing
- BAN2401 2.5 mg/kg, BAN2401 5 mg/kg, BAN2401 10 mg/kg
- Where
- 4 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Eisai Co., Ltd.
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease.
- Conditions
- Coronary Microvascular Dysfunction, Coronary Microvascular Disease, Microvascular Coronary Artery Disease
- Trial name
- FREEDOM (NCT04614467)
- Testing
- CLBS16
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- Lisata Therapeutics, Inc.
Central Sleep Apnea, Heart Failure
Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea
Central sleep apnea (CSA) has been associated with increased mortality and primarily occurs in patients with heart failure (HF).
- Trial name
- NCT01414309
- Where
- 4 sites in United States, Germany
- Volunteers
- 5 people
- Sponsor
- Respicardia, Inc.
Cognitive Dysfunction, Dementia, Mild
FitMi AD Home Therapy for Individuals With MCI or Mild Dementia Due to Alzheimer's Disease
This study will investigate the efficacy of a newly developed exercise device (FitMi AD) for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease.
- Trial name
- NCT05504811
- Testing
- FitMi AD, Conventional exercise program
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Flint Rehabilitation Devices, LLC
HIV Infections
Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy
The purpose of the study is to gain initial information on the tolerability and feasibility of high-concentration capsaicin patches for the treatment of painful HIV-associated neuropathy, whether resulting from HIV disease and/or…
- Trial name
- NCT00061152
- Testing
- Capsaicin Dermal Patch
- Where
- 3 sites in United States
- Sponsor
- NeurogesX
Alzheimer Disease, Cognitive Impairment
The REMIND Study- SPARK Neuro Software Study
The study utilizes investigational software, the SPARK Test, with an FDA-cleared electroencephalography (EEG) amplifier and EEG cap to collect and patient EEG data.
- Trial name
- NCT05406778
- Testing
- SPARK Test
- Where
- 7 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Spark Neuro Inc.